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Abstract: Integrase inhibitors represent an important new class of antiretroviral drugs. 
  Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval 
appears to be a promising once-daily agent when combined with other antiretroviral drugs. 
Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no spe-
cific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as 
a fixed-dose combination. However, the drug requires boosting and this leads to a number of 
drug–drug interactions and necessary dose adjustment when dosing with certain drugs, including 
dose reduction in the presence of atazanavir, lopinavir, rifabutin, and ketoconazole, and dose 
increase for ethinyl estradiol when co-administered with boosted elvitegravir. The main advantage 
of elvitegravir lies in its potential to be administered as a once-daily, single pill. Limitations 
include dose adjustment requirements, a relatively low genetic barrier to resistance, high price, 
and lack of data for use in children. Clinical trials addressing specific challenges encountered 
in resources-limited settings should be encouraged.
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Introduction
The last 10 years have been hailed as a “golden decade of antiretroviral drug 
development.”1 Almost half of all new chemical entities approved by the US Food 
and Drug Administration to treat human immunodeficiency virus (HIV) infection 
since 1986 were approved in the years since 2000, and these approvals span a range 
of different drug classes that target different stages of viral replication.1
Among these new drug classes, the integrase inhibitor class has been welcomed as 
offering a new approach to treating treatment-experienced individuals who are resis-
tant to older generation drugs. Raltegravir, the first licensed integrase inhibitor, had 
been approved for use in treatment-naïve and treatment-experienced HIV-1 infected 
adults.2   Elvitegravir, the second integrase inhibitor that will be submitted for regula-
tory approval appears to be a promising once-daily agent when combined with other 
antiretroviral drugs. Elvitegravir is administered as a once-daily integrase inhibitor that 
needs boosting by either ritonavir or cobicistat. Clinical studies in experienced patients 
have assessed both ritonavir and cobicistat as booster; elvitegravir is being tested as 
first-line drug in a fixed-dose combination (“Quad”) including tenofovir, emtricitabine, 
cobicistat and elvitegravir. Quad was submitted to the US Food and Drug Administra-
tion for regulatory approval for use in naïve patients in late 2011.
In resource-limited settings tremendous progress has been made over the last decade 
with now over 6 million individuals estimated to be receiving antiretroviral therapy (ART). 
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However, this represents less than half of the clinical need.3 The 
first priority, therefore, remains to ensure that more patients are 
able to access first-line ART. Nevertheless, ART availability has 
been gradually increasing over the last decade, and consistent 
with experience from developed countries, a growing number 
of patients are moving to second-line therapy,4 and a propor-
tion of these patients are reported to be failing second-line 
therapy.5,6 Thus, it is important to consider to what extent new 
drugs and new drug classes meet the requirements of patients 
and programs in resource-limited settings. Drug specifications 
for use in resource-limited settings may be more stringent than 
for developed countries as issues such as treatment durabil-
ity, feasibility of manufacturing fixed-dose combination, and 
the possibility of being used without biological or virological 
monitoring are even more important.
In this review, we summarize the available information on 
the pharmacokinetics, safety, and efficacy of elvitegravir with 
an emphasis on issues of particular relevance to resource-
limited settings.
Search strategy
We searched the following databases from inception to March 
2011 for articles containing elvitegravir or GS-9137/JTK-303: 
MEDLINE via PubMed (www.ncbi.nlm.nih.gov/pubmed), 
EMBASE (www.embase.com), and the Cochrane Central 
Register of Controlled Trials (www.thecochranelibrary.com). 
We also searched the websites of major HIV conferences, 
ie, all international acquired immune deficiency syndrome 
(AIDS) society conferences (up to Rome, July 2011), all 
conferences on retroviruses and opportunistic infections 
(up to Boston, March 2011), all abstracts from international 
workshops on clinical pharmacology of HIV therapy, and all 
abstracts from the international congresses on drug therapy in 
HIV infection (up to Glasgow, November 2010). No language 
restrictions were applied. We included all articles reporting 
original data on pharmacokinetics, tolerability, safety, and 
efficacy. This information was crosschecked against data pre-
sented in secondary reports (nonsystematic reviews, opinion 
articles, and news items). We also searched in the clinicaltrial.
gov website (www.clinicaltrials.gov) to obtain information 
about ongoing studies. Finally, we complemented the search 
by reviewing bibliographies of relevant papers. The initial 
search yielded 481 titles, from which 14 full text articles and 
eleven conference abstracts were retained for full review.
Pharmacology of drug action
Elvitegravir (also known as GS-9137 or JTK-303) has 
the chemical name 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-
1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid],7 a molecular weight 
of 447.88 g/mol, and the molecular formula C23H23CIFNO5.8 
It is part of the integrase inhibitor class of drugs that work by 
inhibiting HIV-1 strand transfer and integration. Integrase is 
one of the three enzymes required of HIV replication. Its pri-
mary role is to integrate the viral DNA into the cellular DNA 
of the host. Elvitegravir inhibits the integrase enzyme at this 
vital step, blocking viral DNA strand transfer and integration, 
allowing it to be metabolized by cellular enzymes. The lack of 
a functionally equivalent enzyme to integrase in human cells 
reduces the potential for drug-induced cytotoxicity.9
Pharmacokinetics
The absorption of elvitegravir increases three-fold in the pres-
ence of food.10 It reaches a Cmax at 3–4 hours. Its half-life (t½) 
when dosed alone is approximately 3 hours while boosting 
with ritonavir 100 mg prolongs t½ to 9 hours.7   Pharmacokinetic 
data from dose finding studies in HIV-1 infected patients sug-
gest that maintenance of effective trough concentrations are 
essential for antiviral activity.7
Elvitegravir undergoes metabolism primarily by the cyto-
chrome (CYP) 3A4/5 and partly by glucuronidation of uridine 
glucuronosyltransferase (UGT) 1A1 and 1A3.11 The main 
metabolites, M1 and M4, are less potent than parent compounds 
and are not considered to contribute to the antiviral activity of 
elvitegravir. A study assessing excretion of a [14C] fluorescence 
tagged elvitegravir/ritonavir 50/100 mg dose found that 94.8% 
was recovered in feces while 6.7% was recovered in urine.11 
In this study, once-daily elvitegravir with boosted ritonavir 
achieved a higher trough concentration compared to elvitegravir 
dosed twice-daily without boosting, achieving $3-fold inhibi-
tory quotient (using protein-binding adjusted IC50).7 Ritonavir 
boosting above 100 mg does not result in additional increases in 
elvitegravir exposure.12 There is no difference between boosting 
with 100 mg ritonavir and 150 mg cobicistat.13
Pharmacokinetics of elvitegravir 
drug–drug interactions
The main results of drug–drug interaction studies are 
described below and summarized in Table 1.
Interactions with key drugs  
in the management of HIV/AIDS
Tuberculosis drugs
A pharmacokinetic study among 19 healthy volunteers 
assessed the potential interaction between elvitegravir/
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ritonavir (r) (300 mg/100 mg QD) and the tuberculosis drug 
rifabutin (RFB) (150 mg every other day). Exposures of RFB 
measured by RFB levels were not altered while its metabolite 
25-O-dcRFB was increased 5–20 fold.14 Total antimicrobial 
activity was increased by 50% during co-administration. 
Three subjects terminated the study prematurely due to a 
grade 4 adverse event (neutropenia). Most adverse events 
were mild (mainly nausea and headache). The results of this 
study showed that elvitegravir/ritonavir can be given at a 
reduced RFB dose of 150 mg every other day with appropri-
ate monitoring of adverse events. The interaction between 
elvitegravir/ritonavir and rifampicin, the more common 
tuberculosis drug used in resource-limited settings, has not 
been studied, but is expected due to the inhibition of CYP 
3A4 and UGT 1A by rifampicin of which are substrates of 
elvitegravir.
Antiretrovirals
Drug interaction pharmacokinetic (PK) studies were exten-
sively conducted with at least five protease inhibitors (PIs): 
darunavir/ritonavir (DRV/r), tipranavir/ritonavir (TPV/r), fos-
amprenavir/ritonavir (FPV/r), atazanavir/ritonavir (ATV/r), 
lopinavir/ritonavir (LPV/r).
Forty-six healthy subjects participated in a William 
crossover design PK study evaluating the interaction between 
darunavir/ritonavir (600/100 mg BID) and tipranavir/  ritonavir 
(500/200 mg BID) with elvitegravir (200 mg or 125 mg QD).15 
The Cmax, AUCτ, and Cτ of elvitegravir increased by 13%, 
10% and 18% but decreased for darunavir by 11%, 11% and 
17% respectively when both drugs were given together with 
ritonavir boosting. This falls within protocol-defined lack of 
interaction bounds of 70%-143%. Similarly, the Cmax of elvite-
gravir increased 4% and AUCτ and Cτ decreased 8% and 10% 
respectively when given concurrently with boosted tipranavir, 
while the Cmax, AUCτ, and Cτ of tipranavir decreased by 8%, 
11%, and 11%. The pharmacokinetics of elvitegravir did not 
differ if ritonavir was given once or twice daily. No dosage 
adjustments are therefore needed when boosted tipranavir or 
boosted darunavir are given with elvitegravir.
In another study of fosamprenavir/ritonavir (700/100 mg 
BID) and elvitegravir (125 mg QD), no significant altera-
tions in exposures of elvitegravir, amprenavir and ritonavir 
were reported.16 Significant interaction was noted in a study 
of lopinavir/ritonavir (400/100 mg BID) and elvitegravir 
(125 mg QD) administered to health volunteers, in which 
Cmax, AUCτ, and Cτ of elvitegravir increased by 52%, 75% 
and 139% respectively.17 No significant change in exposures 
were seen in lopinavir concentrations. All adverse events 
were grade 1 in severity with headache (elvitegravir/r) and 
diarrhea (both LPV/r and elvitegravir plus LPV/r) being the 
most common. Following a PK simulation study an elvite-
gravir dose reduction to 85 mg was recommended when 
co-administered with LPV/r.17
As atazanavir, elvitegravir, and ritonavir share similar 
elimination pathways, two PK studies were carried out to 
identify the interaction and to confirm a dose adjustment of 
elvitegravir when dosed with boosted atazanavir in 33 healthy 
subjects. In the first study co-administration of elvitegravir 
(200 mg) and atazanavir/r (300/100 mg) resulted in a one- to 
two-fold increase in elvitegravir Cmax, AUCτ, and Cτ while 
atazanavir exposures decreased by 16%, 21% and 35% respec-
tively, indicating a significant interaction.18 In the second study, 
elvitegravir administered at 150 mg was compared to dose 
adjusted elvitegravir 85 mg and atazanavir/r (300/100 mg) 
in 20 healthy subjects. Elvitegravir exposures at 85 mg 
when co-administered with atazanavir/r 300/100 mg were 
similar to elvitegravir 150 mg. Atazanavir exposures were 
not significantly altered by elvitegravir at 85 mg. Therefore, 
dose adjustment of elvitegravir 85 mg is recommended when 
administered with atazanavir/r 300/100 mg. Since atazanavir 
is an inhibitor of CYP 3A and UGT 1A1, another study was 
designed to examine the interaction between elvitegravir with 
unboosted atazanavir.19 A crossover design study carried out 
on 15 healthy subjects who were given elvitegravir/ritonavir 
300/100 mg for 10 days and then atazanavir 400 mg and elvite-
gravir 300 mg for 10 days confirmed that atazanavir boosting 
of elvitegravir was mainly via CYP 3A. There was a modest 
decrease in elvitegravir Cτ by 10% which is still .10-fold in 
vitro IC95. Atazanavir Cτ and AUCτ when given with elvite-
gravir were lower than historical values.
In a drug interaction study between elvitegravir/ritonavir 
(150/100 mg QD) and maraviroc (150 mg BID) in 28 healthy 
subjects, the pharmacokinetics of elvitegravir and ritonavir 
were not altered while maraviroc exposures increased, with a 
two- to four-fold increase in Cmax, AUCτ, and Cτ.20 This inter-
action was expected as maraviroc is a known substrate for 
CYP 3A4 and P-glycoprotein (Pgp) transporter and ritonavir 
is a known CYP 3A/Pgp inhibitor. As the exposures of mara-
viroc are within the range of those observed when maraviroc 
is co-administered with other potent CYP 3A4 inhibitors, the 
study recommended a reduction in maraviroc dose to 150 mg 
BID when co-administered with elvitegravir/ritonavir.
A study of elvitegravir/ritonavir (150/100 mg QD) and 
etravirine (200 mg BID) found no significant changes in 
the exposures of elvitegravir, ritonavir or etravirine.21 The 
overlapping metabolic pathways of both drugs proved in 
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Table 1 Interactions between elvitegravir ± ritonavir and other drugs
Co-administered  
drug
Participants  
(completed  
study)
Duration Dose PK elvitegravir in % change PK co-administered  drug in % change Comments
Elvitegravir ±  
ritonavir
Co-administered drug Cmax AUCτ Cτ Cmax AUCτ Cτ
Zidovudine23 28 healthy  
subjects
27 days 200 mg + 100 mg QD  
day 8–27
300 mg BID day 1–7, 8–17 ↑5% ↑5% ↑15% ↓12% ↓14% NA No dosage adjustment  
needed
Didanosine23,* 32 healthy  
subjects
17 days 200 mg + 100 mg QD  
day 5, 14–17
400 mg (EC capsule) QD  
day 1, 15
↓5% ↓3% ↑6% ↓16% ↓14% NA No dosage adjustment  
needed
Stavudine23,* 32 healthy  
subjects
17 days 200 mg + 100 mg QD  
day 5, 14–17
40 mg QD day 3, 17 ↓4% ↓2% ↑24% ↓0.4% ↑7% NA No dosage adjustment  
needed
Abacavir23 26 healthy  
subjects
15 days 200 mg + 100 mg QD  
day 5–15
600 mg day 1, 15 ↓5% ↓3% ↑6% ↓12% ↓17% NA No dosage adjustment 
needed
Rifabutin14 19 healthy  
volunteers
53 days 300 mg + 100 mg QD 150 mg EOD ↓8% ↓4% ↓6% Rifabutin: ↓8% 
25-o-dcRFB:  
↑440%
Rifabutin: ↓6% 
25-o-dcRFB:  
↑851%
Rifabutin: ↑16% 
25-o-dcRFB:  
↑1836
Dose adjustment of  
rifabutin 150 mg EOD  
recommended with  
monitoring of adverse  
events
Atazanavir  
(boosted)19
53 healthy  
subjects
Study 1: 14 days,  
Study 2: 10 days
Study 1: 200 mg 
Study 2: 85 mg
300 mg + ritonavir 100 mg QD Study 1: ↑85 
Study 2: ↓9
Study 1: ↑100 
Study 2: ↑7
Study 1: ↑188 
Study 2: ↑38
Study 1: ↓16 
Study 2: ↓3
Study 1: ↓21 
Study 2: ↓11
Study 1: ↓35% 
Study 2: ↓17
Dose adjustment of EVG   
85 mg recommended  
when co-administered  
with ATV/r 300/100 mg
Atazanavir  
(unboosted)18
15 healthy  
subjects
20 days 300 mg 400 mg ↑8% ↑7% ↓10% 3680 ng/mL 16300 ng ⋅ h/mL 74.5 ng/mL Atazanavir exposures  
are lower than historical  
values
Darunavir§,15 20 healthy  
subjects
42 days 125 mg QD 600 mg + ritonavir 100 mg BID ↑13% ↑10% ↑18% ↓11% ↓11% ↓17% No dosage adjustment  
needed
Tipranavir§,15 26 healthy  
subjects
42 days 200 mg QD 500 mg + ritonavir 200 mg BID ↑4% ↓8% ↓10% ↓8% ↓11% ↓11% No dosage adjustment  
needed
Fosamprenavir16 31 healthy  
subjects
28 days 125 mg QD 700 mg + ritonavir 100 mg BID No change ↓7% ↓4% ↓2% ↓1% ↑1% No dosage adjustment  
needed
Lopinavir17 27 healthy  
subjects
14 days 125 mg QD 400 mg + ritonavir 100 mg BID ↑52% ↑75% ↑139% ↓1% ↓3% ↓8% Dose reduction of  
elvitegravir to 85 mg  
is recommended
Maraviroc20 28 healthy  
subjects
20 days 150 mg + 100 mg QD 150 mg BID ↑1% ↑7% ↑9% ↑115% ↑186% ↑323% Dose adjustment of  
maraviroc 150 mg BID  
recommended
Etravirine21 31 healthy  
volunteers
20 days 150 mg + 100 mg QD 200 mg BID ↑7% ↑6% ↑6% ↑2% ↓2% ↓10% No dosage adjustment  
needed
Antacid24,σ 62 healthy  
subjects
Study 1: 11 days 
Study 2: 15 days
50 mg + 100 mg QD 20 mL together, 2 hours before,  
2 hours after, 4 hours before,  
4 hours after elvitegravir
Together with antacid: ↓47% 
2 hours after antacid: ↓18% 
4 hours after antacid: ↓5% 
2 hours before antacid: ↓2% 
4 hours before antacid: ↓ 21%
Together with antacid: ↓45% 
2 hours after antacid: ↓15% 
4 hours after antacid: ↓4% 
2 hours before antacid: ↓2% 
4 hours before antacid: ↓20%
Together with antacid: ↓41% 
2 hours after antacid: ↓10% 
4 hours after antacid: ↑4% 
2 hours before antacid: no change 
4 hours before antacid: ↓20%
NA NA NA Administration of  
antacid and EVG should  
be separated by at least  
2 hours
Omeprazole24,σ 62 healthy  
subjects
15 days 50 mg + 100 mg QD 40 mg QD ↓7% ↓1% ↓6% NA NA NA No dosage adjustment  
needed
Ketoconazole23 18 healthy  
subjects
15 days 150 mg + 100 mg QD 200 mg BID ↑17% ↑48% ↑67% NA NA NA Maximum recommended   
daily dose of  
ketoconazole is 200 mg
Norgestimate and  
ethinyl estradiol24
15 healthy  
subjects
56 days 150 mg + cobicistat  
150 mg + tenofovir  
300 mg + emtricitabine  
200 mg
Combination oral  
contraceptive pill containing 
norgestimate (NGM) 0.180 mg,  
0.215 mg, 0.250 mg and ethinyl  
estradiol (EE) 25 μg
NA NA NA EE: ↓6% 
NGMN: ↑109%
EE: ↓25% 
NGMN: ↑126%
EE: ↓41% 
NGMN: ↑167%
Recommended ethinyl  
estradiol dose of the  
oral contraceptive is  
30 μg
Notes: *Pharmacokinetic study of both didanosine and stavudine with elvitegravir was carried out in the same subjects; §pharmacokinetic study of both darunavir and 
tipranavir with elvitegravir was carried out in crossover design in the same subjects; σpharmacokinetic study of both antacid and omeprazole with elvitegravir was carried 
out in one study design.
Abbreviations: PK, pharmacokinetic; GMR, geometric mean ratio; Cmax, maximum concentration; AUCτ, area under the curve from time 0 to tau, where tau is the length 
of dosing interval; Cτ, tau concentration; NA, not available; QD, once a day; BID, twice a day; EOD, every other day; EC, enteric coated; EE, ethinyl estradiol; NGM, 
norgestimate; NGMN, norelgestromin (metabolite of norgestimate).
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  significant and thus no dosage adjustment is warranted 
when they are given concomitantly. The potential interaction 
between elvitegravir/ritonavir and commonly used nucleo-
side reverse transcriptase inhibitors (NRTIs) zidovudine, 
didanosine, stavudine, abacavir, tenofovir and emtricitabine 
have also been studied.22,23 No significant change in exposures 
of these NRTIs or elvitegravir were found.
Acid-reducing agents
A study investigating the effect of acid-reducing agents 
such as antacid and omeprazole, a proton pump inhibitor, 
on elvitegravir exposures24 found no significant change 
in exposures of elvitegravir when administered with 
omeprazole, indicating a lack of influence of gastric pH on 
elvitegravir absorption. Cmax, AUCτ, and Cτ of elvitegravir 
were affected by concomitant antacid administration, with 
observed decreases of 47%, 45% and 41% respectively. 
However, when elvitegravir was given at least 2 hours apart 
from antacid, exposures of elvitegravir were not significantly 
altered. Therefore, co-administration of elvitegravir/ritonavir 
and antacid should be separated by at least 2 hours.
Other drugs
Ketoconazole, a well-known CYP 3A inhibitor and UGT 1A1 
and 2B7 inhibitor was studied in co-administration with rito-
navir-boosted elvitegravir and midazolam is used as a probe 
to measure additional CYP 3A inhibition.   Ketoconazole 
was dosed at 200 mg BID (at days 12–15), elvitegravir/r 
150/100 mg QD (days 2–15) and midazolam single dose 
on days 1, 11 and 15 in 18 healthy subjects.25 Elvitegravir 
exposures as measured by Cmax, AUCτ, and Cτ increased by 
17%, 48%, and 67% respectively. There was an additional 
1%–1.5% CYP 3A inhibition with ketoconazole compared to 
baseline of expected CYP 3A inhibition by ritonavir-boosted 
elvitegravir. As a result of this study a maximum daily dose 
of ketoconazole 200 mg is recommended.
A PK study of the fixed-dose combination of tenofovir 
disoproxil fumarate 300 mg, emtricitabine 200 mg; elvitegra-
vir 150 mg; cobicistat 150 mg; and oral contraceptive (OC) 
pill containing norgestimate 0.180 mg, 0.215 mg, 0.250 mg, 
and ethinyl estradiol 25 μg were carried out over a period 
of two pill cycles in 15 healthy subjects.26 The exposures of 
elvitegravir and cobicistat were within the range of those 
reported in previous studies. However, it was noted that the 
exposures of ethinyl estradiol, Cmax, AUCτ, and Cτ decreased 
by 6%, 25% and 41% respectively. Measurement of serum 
progesterone, follicle stimulating hormone and luteinizing 
hormone were found to be unchanged in both OC with or 
without the fixed-dose combination. A dose of 30 μg of   
ethinyl estradiol is needed for adequate contraception when 
co-administered with the FDC.
Interactions between antiretroviral drugs and antimalarial 
drugs are an important consideration for resource-limited 
settings. However, we were unable to find any data in this 
regard.
Clinical efficacy
Two randomized trials have been conducted to assess the 
efficacy of elvitegravir across a range of doses. The first was 
a randomized dose-ranging monotherapy study in which 40 
HIV-infected patients received elvitegravir (200 mg, 400 mg, 
or 800 mg twice a day; or 50 mg once a day co-administered 
with 100 mg ritonavir) for 10 days; this study found a sig-
nificant reductions in HIV RNA in both treatment-naïve and 
experienced patients compared to placebo.7 No patients in this 
study developed resistance mutations to GS-9137 or other 
antiretroviral agents. The second trial was a Phase II random-
ized, controlled, 48-week study assessing noninferiority of 
elvitegravir at 20 mg, 50 mg, and 125 mg doses to ritonavir-
boosted protease inhibitor in 278 treatment-experienced 
subjects.27 The lowest dose arm was stopped early due to 
inferiority; the 50 mg arm demonstrated noninferiority and 
the 125 mg arm demonstrated superiority. The study also 
established superior virological suppression for those patients 
who were given at least one additional active drug in addition 
to elvitegravir. There was no relationship between elvitegravir 
dosage and adverse events.
The dose chosen for Phase III trial was elvitegravir 
150 mg in the absence of LPV/r or ATZ/r in the background 
regimen (in which case the dose of 85 mg is recommended 
due to pharmacokinetic interactions).
Elvitegravir has been co-formulated as a single tab-
let together with the pharmacologic enhancer cobicistat 
(GS-9350), emtricitabine, and tenofovir (formulated as a 
fixed-dose single tablet known as “Quad”) for use in patients 
with no previous ART experience (naïve patients). Cobicistat 
is a CYP3A4 inhibitor with no antiviral activity, but is being 
tested as a pharmaco-enhancer with elvitegravir and also as a 
PK booster of protease inhibitors as a potential alternative to 
ritonavir.28 Data on the safety and efficacy of Quad are available 
from several trials. In a published Phase II, 48-week random-
ized trial in 71 treatment-naïve HIV-positive patients, Quad   
was found to have comparable efficacy to efavirenz/
emtricitabine/tenofovir (EFV/FTC/TDF):29 at 48 weeks of 
treatment; 90% of the patients taking Quad and 83% of 
patients taking EFV/FTC/TDF achieved a viral load , 50 
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copies/mL. Treatment with Quad was associated with more 
rapid achievement of virological suppression compared to 
EFV/FTC/TDF. Results from two other trials have recently 
been released early by Gilead Sciences but have yet to be 
published.30 In the first trial, patients were randomized to 
receive either EFV/FTC/TDF or Quad over 96 weeks. Interim 
results demonstrated noninferior virological suppression at 
48 weeks. The second trial, comparing Quad versus ritonavir-
boosted atazanavir and truvada over a 96-week period also 
found noninferiority of Quad compared to boosted atazanavir 
in treatment-naïve patients.
Finally, a randomized trial comparing the efficacy 
and safety of raltegravir versus elvitegravir in treatment-
  experienced patients has recently reported 48-week results. 
In this study 351 patients receiving ritonavir-boosted once-
daily elvitegravir 150 mg (or 85 mg in those receiving a back-
ground protease inhibitor of either atazanavir or   lopinavir) 
were compared against 351 receiving ritonavir-boosted twice-
daily raltegravir 400 mg. Each agent was given in combina-
tion with an optimized background regimen. After 48 weeks 
of treatment, using the time to loss of virologic response 
algorithm, 59% of elvitegravir-treated patients achieved and 
maintained a viral load below 50 copies/mL, compared with 
58% of raltegravir-treated patients (intention-to-treat analysis 
P = 0.001).31 Unfortunately, in the preliminary results of trial, 
elvitegravir did not show a greater barrier to resistance when 
compared with raltegravir.31
Safety and tolerability
In the Phase II randomized trial that compared elvitegravir 
with ritonavir-boosted PIs,27 the occurrence of adverse events 
and grade 3 or 4 laboratory toxicity was similar across treat-
ment groups. The most common treatment-emergent adverse 
events were diarrhea and nausea. Three serious adverse events 
across all treatment groups were considered to be related or 
possibly related to study drugs: syncope in a subject exposed 
to elvitegravir 50 mg, a significant hypersensitivity reaction 
in a subject with a history of multiple drug allergies exposed 
to elvitegravir 20 mg, and right eye hyphema in a subject 
receiving the ritonavir-boosted protease inhibitor. No dose-
dependent increase in type of adverse event was observed in 
the elvitegravir arm. None of the three deaths were observed 
in the elvitegravir arm (one was due to   Pneumocystis pneu-
monia, one was due to B cell lymphoma, and one was due 
to cardiorespiratory failure) or were considered to be related 
to the study drug.
The Phase II trial of Quad versus EFV/FTC/TDF con-
cluded that Quad resulted in a lower percentage of drug-re-
lated adverse events compared with EFV/FTC/TDF (35% vs 
57%, respectively). In particular, Quad induced fewer central 
nervous system and psychiatric events. The most common 
adverse events observed in both study arms were: abnormal 
dreams/nightmares, dizziness, fatigue, somnolence,   diarrhea, 
and headache.29 Glomerular filtration remained within the 
normal range and no participant experienced a clinical 
adverse event or discontinued study drug due to changes in 
serum creatinine or renal function. Incidence of laboratory 
abnormalities was similar between the two arms of the study. 
There were no grade 3/4 adverse events nor adverse events 
leading to discontinuation of the study in the Quad group of 
patients, while two grade 3/4 adverse events were reported 
among EFV/FTC/TDF patients and one patient taking EFV/
FTC/TDF left the study early due to an adverse events. These 
data suggest that the Quad could represent a one-pill, once-
daily treatment alternative for the treatment-naïve patient.
Data on efficacy, safety, and tolerability are summarized 
in Table 2.
Perspectives for resource-limited 
settings
The important characteristics of drugs from the perspective of 
resource-limited settings are efficacy, robustness, affordability, 
minimal side-effects (and so minimal laboratory monitoring 
requirements), compatibility with drugs to treat tuberculosis 
and other common co-infections, safety in women of child-
bearing age and children, availability as fixed-dose combina-
tions, and suitability for long-acting formulations.32
Elvitegravir has demonstrated good efficacy and safety, 
with minimal side effects and no specific requirements in 
terms of laboratory monitoring. In addition, elvitegravir is 
available in a triple fixed-dose combination allowing for 
coformulated single-pill administration. However, elvite-
gravir requires boosting by either ritonavir or cobicistat and 
is prone to a number of important drug–drug interactions. In 
addition, it has a relatively low genetic barrier to resistance 
(lower than for protease inhibitors), with just one to two 
mutations needed to result in marked reductions in virus 
susceptibility.33 The potential for resistance development to 
elvitegravir has been assessed in a number of in vitro selec-
tion experiments. Primary resistance-conferring mutations 
occur at positions T66, E92, and Q148;34–36 these mutations 
were also selected for in vivo and resulted in virological 
failure of elvitegravir-based therapies.37 Primary resistance 
mutations are associated with secondary mutations, which 
have been shown to further diminish the susceptibility to 
elvitegravir or play a role in partially restoring viral fitness. 
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Secondary mutations selected under elvitegravir include 
H114Y, L74M, R20K, A128T, E138K, and S230R.38,39
Importantly, two of the three most common raltegravir-
associated mutation pathways also result in elvitegravir 
  resistance (Q 148 H/K/R, N155H).33 However, elvitegravir can 
be used in the presence of Y143, a resistance mutation induced 
by raltegravir.40 The clinical relevance of integrase muta-
tions will require longer-term follow-up. In the clinical trial 
comparing raltegravir to elvitegravir in experienced patients 
there was no difference in the number of selected mutations 
within the two regimens – so elvitegravir robustness may not 
be greater in these preliminary results when compared to the 
first generation integrase inhibitor raltegravir.
The main advantage of elvitegravir lies in its potential to 
be administered as a once-daily, single pill. Dose modifica-
tion in the presence of different protease inhibitors (such as 
atazanavir and lopinavir) can be seen as an advantage (lower 
dosage required) or a disadvantage (complexity of dosage). 
Either way, this relative ease of administration is offset against 
the relatively low barrier to resistance development.
Data on the safety and efficacy of elvitegravir in children 
are lacking. Given that children tend to have a higher rate of 
virological failure compared with adults,41 the relevance of 
elvitegravir as a therapeutic option for treatment-experienced 
children needs to be explored.
Finally, the price of elvitegravir, including any potential 
preferential pricing for resource-limited settings, is unclear. 
However, as the drug has recently been licensed to the Medi-
cines Patent Pool for generic competition and supply to 99 
developing countries, generic competition can be expected to 
lead to lower prices in the countries covered by the agreement. 
The only currently available integrase inhibitor, raltegravir, 
is priced out of reach of most developing countries, cost-
ing over US$5870 per patient per year in some developing 
countries.42
Conclusion
Integrase inhibitors represent an important new class of 
antiretroviral drugs. The favorable efficacy, safety and toler-
ability profile of the first integrase inhibitor licensed for use, 
raltegravir, rapidly advanced prescribing and raltegravir is 
now one of the preferred agents for the treatment of naïve 
subjects in US treatment guidelines.43 Similarly, elvitegravir 
has demonstrated potent antiviral activity and the capac-
ity to induce a rapid virologic response and a favorable 
safety profile.
A number of promising second-generation integrase 
inhibitors are in development. S/GSK-572 (also known as 
dolutegravir) has demonstrated in vitro antiviral activity 
against virus isolates resistant to raltegravir and elvite-
gravir,44,45 and clinical trials are underway to assess the 
activity of this S/GSK-572 in patients failing   raltegravir. 
Pharmacokinetic studies46,47 and dose-ranging trials48,49 
suggest potential for once-daily dosing, low dose (50 mg) 
without the need for boosting, making dolutegravir a good 
candidate for a single-tablet regimen co-formulated pill. A 
second drug, S/GSK-744 likewise appears to be safe and 
effective if administered unboosted as a once-daily dose;50 
and the potential for a long-acting formulation of S/GSK-
744 is also being investigated.51
It remains to be seen what position elvitegravir and other 
integrase inhibitors will take in the treatment guidelines in 
resource-limited settings, and thus to what extent this new 
drug class will benefit the global majority of people liv-
ing with HIV/AIDS. As outlined in this review, a number 
of critically important questions for developing countries 
remain to be answered. Clinical trials addressing specific 
challenges encountered in resource-limited settings should 
be encouraged.
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